Table IV.

Clinical trials testing cancer vaccines for pancreatic cancer.

Antigen & Drug	ClinicalTrials.gov Identifier	Phase	No. of Patients	Status
MUC1 Vaccine (Cvac vaccine)	NCT02310971 ^*	II	0	Withdrawn
Falimarev (MUC1 PANVAC-F vaccine) + Inalimarev (MUC1 PANVAC-V vaccine) + Sargramostim (GM-CSF vaccine)	NCT00669734 ^*	I	18	Ongoing
Telomerase vaccine (GV1001) + gemcitabine + Sargramostim + tadalafil + Radiation Therapy	NCT01342224 ^*	I	11	Active
Telomerase vaccine (GV1001) + Sargramostim + capecitabine + gemcitabine	NCT00425360 ^*	III	1110	Completed
CEA vaccine (ALVAC + vaccinia) + aldesleukin (IL-2) + Sargramostim	NCT00003125 ^*	II	24	Completed
CEA vaccine (AVX701)	NCT00529984 ^*	I & II	28	Completed
Recombinant fowlpox-CEA(6D)/TRICOM vaccine + GM-CSF vaccine + Sargramostim	NCT00028496 ^*	I	48	Completed
Recombinant fowlpox-CEA(6D)/TRICOM vaccine + denileukin diftitox + therapeutic autologous dendritic cells	NCT00128622 ^*	I	24	Completed
CEA vaccine (TRICOM-CEA(6D))	NCT00027534 ^*	I	14	Completed
CEA RNA-pulsed DC cancer vaccine	NCT00004604 ^*	I	24	Completed
CEA vaccine (carcinoembryonic antigen peptide 1-6D) + incomplete Freund’s adjuvant + sargramostim	NCT00012246 ^*	II	7	Terminated
K-ras vaccine (TG01) + GM-CSF + Gemcitabine	NCT02261714 ^*	I & II	32	Active
Aldesleukin + ras peptide cancer vaccine + sargramostim + DetoxPC	NCT00019331 ^*	II	11	Completed
HLA-A^*02:01 -restricted VEGFR1-derived peptide vaccination	NCT00683085 ^*	I & II	2	Terminated
VEGFR-2 DNA vaccine VXM01	NCT01486329 ^*	I	72	Completed
Mesothelin vaccine (CRS-207) + GVAX vaccine + gemcitabine + capecitabine + 5-FU + irinotecan or erlotinib + cyclophosphamide	NCT02004262 [Ref no. 87, 88]	II	303	Completed
GVAX Pancreas + Mesothelin vaccine (CRS-207) + Cyclophosphamide	NCT01417000 [Ref. no. 88]	II	93	Ongoing
Mesothelin vaccine (CRS-207)	NCT00585845 ^*	I	17	Terminated
Cancer stem cell vaccine	NCT02074046 ^*	I & II	40	Completed

Data obtained from https://clinicaltrials.gov/